{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=cohort+1&page=26",
    "query": {
      "intervention": "cohort 1",
      "page": 26
    },
    "page_size": 10
  },
  "pagination": {
    "page": 26,
    "page_size": 10,
    "total_count": 8003,
    "total_pages": 801,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=cohort+1&page=27&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=cohort+1&page=25&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-19T03:43:43.261Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT07231679",
      "title": "A Study to Investigate IGT-303 in Healthy Volunteers and Participants With Chronic Kidney Disease",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Healthy Volunteers",
        "Chronic Kidney Disease"
      ],
      "interventions": [
        {
          "name": "IGT-303",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Ingenia Therapeutics INC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 94,
      "start_date": "2025-10-30",
      "completion_date": "2027-04",
      "has_results": false,
      "last_update_posted_date": "2026-10-07",
      "last_synced_at": "2026-11-19T03:43:43.261Z",
      "location_count": 4,
      "location_summary": "Chula Vista, California • Lakeland, Florida • Statesville, North Carolina + 1 more",
      "locations": [
        {
          "city": "Chula Vista",
          "state": "California"
        },
        {
          "city": "Lakeland",
          "state": "Florida"
        },
        {
          "city": "Statesville",
          "state": "North Carolina"
        },
        {
          "city": "Wilmington",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07231679"
    },
    {
      "nct_id": "NCT04948827",
      "title": "A First-in-Human Study of SBP-9330 in Healthy Subjects",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Smoking Cessation"
      ],
      "interventions": [
        {
          "name": "SBP-9330",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Camino Pharma, LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 90,
      "start_date": "2021-07-20",
      "completion_date": "2023-03-06",
      "has_results": true,
      "last_update_posted_date": "2024-04-16",
      "last_synced_at": "2026-11-19T03:43:43.261Z",
      "location_count": 1,
      "location_summary": "Overland Park, Kansas",
      "locations": [
        {
          "city": "Overland Park",
          "state": "Kansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04948827"
    },
    {
      "nct_id": "NCT00874042",
      "title": "Dose Escalation Study of ARQ 197 in Combination With Gemcitabine in Adult Patients With Advanced Solid Tumors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Advanced Solid Tumors"
      ],
      "interventions": [
        {
          "name": "Treatment with ARQ 197 in combination with gemcitabine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 74,
      "start_date": "2009-03",
      "completion_date": "2011-04",
      "has_results": false,
      "last_update_posted_date": "2012-07-23",
      "last_synced_at": "2026-11-19T03:43:43.261Z",
      "location_count": 4,
      "location_summary": "Atlanta, Georgia • Oklahoma City, Oklahoma • Nashville, Tennessee + 1 more",
      "locations": [
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Oklahoma City",
          "state": "Oklahoma"
        },
        {
          "city": "Nashville",
          "state": "Tennessee"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00874042"
    },
    {
      "nct_id": "NCT05283486",
      "title": "Evaluation of Efficacy, Tolerability, and Pharmacokinetics of MYMD1 for Chronic Inflammation and Sarcopenia/Frailty",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Sarcopenia",
        "Frailty",
        "Aging"
      ],
      "interventions": [
        {
          "name": "MYMD-1 600MG",
          "type": "DRUG"
        },
        {
          "name": "MYMD-1 750mg",
          "type": "DRUG"
        },
        {
          "name": "MYMD-1 900mg",
          "type": "DRUG"
        },
        {
          "name": "MYMD-1 1050mg",
          "type": "DRUG"
        },
        {
          "name": "placebo 600mg",
          "type": "DRUG"
        },
        {
          "name": "placebo 750mg",
          "type": "DRUG"
        },
        {
          "name": "placebo 900mg",
          "type": "DRUG"
        },
        {
          "name": "placebo 1050mg",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "TNF Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "65 Years",
        "maximum_age": "99 Years",
        "sex": "ALL",
        "summary": "65 Years to 99 Years"
      },
      "enrollment_count": 40,
      "start_date": "2022-02-01",
      "completion_date": "2023-06-07",
      "has_results": false,
      "last_update_posted_date": "2023-10-30",
      "last_synced_at": "2026-11-19T03:43:43.261Z",
      "location_count": 3,
      "location_summary": "Clearwater, Florida • Tampa, Florida • Baltimore, Maryland",
      "locations": [
        {
          "city": "Clearwater",
          "state": "Florida"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05283486"
    },
    {
      "nct_id": "NCT04088786",
      "title": "Phase I Trial HIPEC With Nal-irinotecan",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Peritoneal Cancer",
        "Pseudomyxoma Peritonei",
        "Mucinous Adenocarcinoma",
        "Mucinous Tumor",
        "Colorectal Cancer",
        "Gastric Cancer",
        "Primary Peritoneal Carcinoma",
        "Mesothelioma"
      ],
      "interventions": [
        {
          "name": "nanoliposomal irinotecan",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Stony Brook University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 18,
      "start_date": "2019-10-22",
      "completion_date": "2022-04-14",
      "has_results": false,
      "last_update_posted_date": "2022-05-06",
      "last_synced_at": "2026-11-19T03:43:43.261Z",
      "location_count": 2,
      "location_summary": "Lexington, Kentucky • Stony Brook, New York",
      "locations": [
        {
          "city": "Lexington",
          "state": "Kentucky"
        },
        {
          "city": "Stony Brook",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04088786"
    },
    {
      "nct_id": "NCT02045732",
      "title": "A Study To Evaluate The Safety And Tolerability Of PF-06342674 (RN168) In Subjects With Multiple Sclerosis (MS)",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Multiple Sclerosis"
      ],
      "interventions": [
        {
          "name": "PF-06342674 0.25 mg/kg",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "BIOLOGICAL"
        },
        {
          "name": "PF-06342674 1.5 mg/kg",
          "type": "BIOLOGICAL"
        },
        {
          "name": "PF-06342674 6.0 mg/kg",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 4,
      "start_date": "2014-09",
      "completion_date": "2015-10",
      "has_results": true,
      "last_update_posted_date": "2017-01-16",
      "last_synced_at": "2026-11-19T03:43:43.261Z",
      "location_count": 8,
      "location_summary": "Albany, New York • Latham, New York • Cleveland, Ohio + 2 more",
      "locations": [
        {
          "city": "Albany",
          "state": "New York"
        },
        {
          "city": "Latham",
          "state": "New York"
        },
        {
          "city": "Latham",
          "state": "New York"
        },
        {
          "city": "Latham",
          "state": "New York"
        },
        {
          "city": "Cleveland",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02045732"
    },
    {
      "nct_id": "NCT00476216",
      "title": "Fondaparinux (Arixtra) With Chemotherapy for Advanced Non-Small Cell Lung Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Non-Small Cell Lung Cancer",
        "Venous Thromboembolism"
      ],
      "interventions": [
        {
          "name": "Combination of Arixtra with chemotherapy",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Alabama at Birmingham",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "79 Years",
        "sex": "ALL",
        "summary": "18 Years to 79 Years"
      },
      "enrollment_count": 23,
      "start_date": "2007-09",
      "completion_date": "2013-12",
      "has_results": false,
      "last_update_posted_date": "2014-03-05",
      "last_synced_at": "2026-11-19T03:43:43.261Z",
      "location_count": 1,
      "location_summary": "Birmingham, Alabama",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00476216"
    },
    {
      "nct_id": "NCT06509906",
      "title": "M9466 in Combination With Topoisomerase 1 Inhibitors-based Regimens in Advanced Solid Tumors and Colorectal Cancer (DDRiver 511)",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Advanced Solid Tumor"
      ],
      "interventions": [
        {
          "name": "M9466",
          "type": "DRUG"
        },
        {
          "name": "Irinotecan",
          "type": "DRUG"
        },
        {
          "name": "Folinic acid",
          "type": "DRUG"
        },
        {
          "name": "Fluorouracil (5-FU)",
          "type": "DRUG"
        },
        {
          "name": "Bevacizumab",
          "type": "DRUG"
        },
        {
          "name": "Granulocyte colony stimulating factor (G-CSF)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "EMD Serono Research & Development Institute, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 3,
      "start_date": "2024-10-08",
      "completion_date": "2025-12-02",
      "has_results": false,
      "last_update_posted_date": "2025-12-18",
      "last_synced_at": "2026-11-19T03:43:43.261Z",
      "location_count": 4,
      "location_summary": "Denver, Colorado • Pennington, New Jersey • Nashville, Tennessee + 1 more",
      "locations": [
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Pennington",
          "state": "New Jersey"
        },
        {
          "city": "Nashville",
          "state": "Tennessee"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06509906"
    },
    {
      "nct_id": "NCT05827926",
      "title": "A Study of mRNA-based Influenza and SARS-CoV-2 (COVID-19) Multi-component Vaccines in Healthy Adults",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "SARS-CoV-2",
        "Influenza"
      ],
      "interventions": [
        {
          "name": "Influenza Vaccine 1",
          "type": "BIOLOGICAL"
        },
        {
          "name": "mRNA-1083.1",
          "type": "BIOLOGICAL"
        },
        {
          "name": "mRNA-1083.2",
          "type": "BIOLOGICAL"
        },
        {
          "name": "mRNA-1083.3",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Investigational Influenza Vaccine 1",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Investigational COVID-19 Vaccine 1",
          "type": "BIOLOGICAL"
        },
        {
          "name": "COVID-19 Vaccine 1",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Investigational Influenza Vaccine 2",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Influenza Vaccine 2",
          "type": "BIOLOGICAL"
        },
        {
          "name": "mRNA-1083",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Investigational COVID-19 Vaccine 2",
          "type": "BIOLOGICAL"
        },
        {
          "name": "COVID-19 Vaccine 2",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "ModernaTX, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "79 Years",
        "sex": "ALL",
        "summary": "18 Years to 79 Years"
      },
      "enrollment_count": 1758,
      "start_date": "2023-04-14",
      "completion_date": "2024-12-03",
      "has_results": true,
      "last_update_posted_date": "2025-12-23",
      "last_synced_at": "2026-11-19T03:43:43.261Z",
      "location_count": 69,
      "location_summary": "Chandler, Arizona • Colton, California • Huntington Beach, California + 59 more",
      "locations": [
        {
          "city": "Chandler",
          "state": "Arizona"
        },
        {
          "city": "Colton",
          "state": "California"
        },
        {
          "city": "Huntington Beach",
          "state": "California"
        },
        {
          "city": "Modesto",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05827926"
    },
    {
      "nct_id": "NCT04235764",
      "title": "En-bloc Transurethral Resection of Bladder Tumor (En-bloc TURBT) Specimens Using a Redesigned Surgical Resectoscope Device",
      "overall_status": "RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Bladder Cancer"
      ],
      "interventions": [
        {
          "name": "modified resectoscope",
          "type": "DEVICE"
        },
        {
          "name": "TURBT",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "DEVICE",
        "PROCEDURE"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "120 Years",
        "sex": "ALL",
        "summary": "18 Years to 120 Years"
      },
      "enrollment_count": 25,
      "start_date": "2020-09-09",
      "completion_date": "2029-09-30",
      "has_results": false,
      "last_update_posted_date": "2026-10-29",
      "last_synced_at": "2026-11-19T03:43:43.261Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04235764"
    }
  ]
}